Heterologous SARS-CoV-2 booster vaccine for individuals with hematological malignancies after a primary SARS-CoV-2 mRNA vaccine series.
Saved in:
| Title: | Heterologous SARS-CoV-2 booster vaccine for individuals with hematological malignancies after a primary SARS-CoV-2 mRNA vaccine series. |
|---|---|
| Authors: | Sherman AC; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA; Dana-Farber Cancer Institute, Boston, MA, USA; Precision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: acsherman@bwh.harvard.edu., van Haren SD; Precision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Borberg E; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA., Swank Z; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA., Aleissa M; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA; Dana-Farber Cancer Institute, Boston, MA, USA; Department of Pharmacy Practice, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia., Tong A; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA., Rooks R; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA; Emory School of Medicine, Atlanta, GA, USA., Kanwal U; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA., Levine H; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA., Yates B; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA., Izaguirre N; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA., Ryff K; Precision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA., Thomas S; Precision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Parisi L; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA., Li X; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA., Walt DR; Harvard Medical School, Boston, MA, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA., Levy O; Precision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT & Harvard, Cambridge, MA, USA., Walsh SR; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Issa NC; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA; Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Baden LR; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA; Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. |
| Source: | Vaccine [Vaccine] 2024 Sep 17; Vol. 42 (22), pp. 126054. Date of Electronic Publication: 2024 Jun 10. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
